$IVC (Invacare Corporation)

$IVC {{ '2016-10-03T11:33:50+0000' | timeago}} • Announcement

Distributor of bath safety, personal care, and durable medical equipment, Compass Health Brands, said it it pleased to announce the acquisition of the Professional Medical Imports Division PMI and the ProBasics brand from $IVC, a manufacturer and distributor of innovative home and long-term care medical products.

$SYK {{ '2018-01-09T17:21:37+0000' | timeago}} • Announcement

$SYK said that for 4Q17 its preliminary results are of net sales growth of 10% to $3.5Bil, while for FY17, its net sales grew 9.9% to $12.4Bil. Excluding the impact of foreign currency & acquisitions, net sales rose 8.1% and 7.1% in 4Q17 and FY17. For 2018, $SYK expects modest headwinds that will be manageable within its overall financial targets.

$HRC {{ '2018-01-09T17:07:14+0000' | timeago}} • Announcement

$HRC announced its preliminary 1Q18 revenue. For this period, the company expects worldwide revenue of approx $670MM, an increase of 5% YoY. Core revenue increased approx 2%, exceeding the company's previously issued guidance of flat core revenue growth.

$AIT {{ '2018-01-09T14:46:20+0000' | timeago}} • Announcement

$AIT has agreed to acquire FCX Performance, Inc. for approx. $768MM. The deal is expected to close within 30 days. The acquisition is expected to contribute about $550MM in sales and $68MM in EBITDA in the first 12 months of applied ownership. The deal is expected to be accretive in FY19 after recognition of one-time transaction costs in FY18.

$LLY {{ '2018-01-08T19:33:20+0000' | timeago}} • Announcement

$LLY join hands with consumer digital health company Livongo Health to study real world behaviors of people affected with diabetes. This collaboration is expected help the diabetic people to better manage their condition.

$EBS {{ '2018-01-08T14:21:21+0000' | timeago}} • Announcement

$EBS expects total revenues to be $715-755MM for full-year 2018. Net income is expected to be $95-110MM while adjusted net income is expected to be $110-125MM. Pretax income is expected to be $120-140MM while EBITDA is expected to be $175-190MM for full-year 2018.

$EBS {{ '2018-01-08T14:21:06+0000' | timeago}} • Announcement

$EBS announced preliminary 2017 financial results. For full-year 2017, $EBS expects total revenue of $555-560MM and BioThrax sales of approx. $286MM. $EBS expects net income to be $80-84MM and adjusted net income to be $92-96MM. Cash and cash equivalents at 2017-end are expected to be approx. $180MM.

$LLY {{ '2017-12-14T18:20:39+0000' | timeago}} • Announcement

$LLY join hands with diabetes management firm Rimidi to provide personalized solutions for diabetic patients who are using insulin. As per the agreement, Rimidi's diabetes management software platform will be integrated with Lilly's insulin management system which is in development.

$LLY {{ '2017-12-13T17:55:28+0000' | timeago}} • Announcement

For 2017, $LLY cut down its GAAP EPS outlook and confirmed its non-GAAP EPS and revenue targets. New products and volume are estimated to drive the low-single digit revenue growth in 2018. Eli Lilly expects to make regulatory progress in 2018 on its rheumatoid arthritis drug baricitinib and migraine drug galcanezumab.

$SYK {{ '2017-12-12T14:28:46+0000' | timeago}} • Announcement

$SYK said Howard Cox Jr. has notified the company that he will not stand for re-election at Stryker's 2018 Annual Meeting, which is expected to be held on May 2, 2018. In light of Cox's immense contributions to the company, he will be named Director Emeritus.

$HLS {{ '2017-12-12T13:23:46+0000' | timeago}} • Announcement

$HLS appointed Nancy Schlichting as an independent director, effective Dec. 11, 2017. With this appointment, the Board will expand to 11 directors. Schlichting currently serves on the boards of $WBA and $HRC.

$SYK {{ '2017-12-11T21:53:53+0000' | timeago}} • Announcement

$SYK said that the simplified public tender offer for the shares and BSAAR warrants of VEXIM has closed. $SYK, which already owned over 50% of the share capital and voting rights of VEXIM, acquired an additional 4.04MM shares during the offer period, as well as 226,520 BSAAR warrants that it has exercised for new shares of VEXIM.

$LLY {{ '2017-12-11T21:06:46+0000' | timeago}} • Announcement

$LLY raised its 1Q18 dividend by 8% to $0.5625 per stock. The dividend is payable on March 9, 2018 to shareholders of record as of Feb. 15, 2018.

$LLY {{ '2017-12-11T17:36:13+0000' | timeago}} • Announcement

FDA accepts to review $LLY's Galcanezumab, an injectionable drug for the treatment of migraine. Rivals $NVS and $AMGN already filed their migraine drug with FDA in July 2017, while $TEVA is also expected to join the race. Lilly's pain portfolio also includes Tanezumab, developed in partnership with $PFE, for the treatment of osteoarthritis.

$LLY {{ '2017-12-11T17:32:54+0000' | timeago}} • Announcement

Kimberly Blackwell, a breast cancer researcher, will be joining $LLY's Oncology division as VP of early phase development and immuno-oncology on March 12, 2018. Dr. Blackwell currently serves as professor of medicine and assistant professor of radiation oncology at Duke University Medical Center.

$ENTL {{ '2017-12-08T17:39:22+0000' | timeago}} • Announcement

Rowley Law PLLC is investigating potential claims against $ENTL and its BoD for breach of fiduciary duty concerning the proposed acquisition of the company by $SYK. Stockholders will receive $24.00 in cash for each share of $ENTL that they hold. The transaction is valued at about $662MM.

$IVC {{ '2017-12-08T13:18:08+0000' | timeago}} • Announcement

$IVC announced a reduction in force in North America that is expected to generate approx. $8.5MM in annualized pretax savings. The company expects to incur total restructuring charges in 4Q17 of approx. $2.6MM on a pretax basis, principally in the NA/HME segment and to a lesser extent in the Institutional Products Group segment.

$SYK {{ '2017-12-07T16:33:56+0000' | timeago}} • Announcement

$SYK agreed to buy $ENTL for $24 per share, or an equity value of about $662MM. The transaction is expected to be dilutive to $SYK's 2018 adjusted EPS by about $0.04 and accretive thereafter. Guggenheim Securities served as financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP served as outside legal counsel for $SYK.

$SYK {{ '2017-12-07T14:25:00+0000' | timeago}} • Announcement

$SYK BoD declared a quarterly dividend of $0.47 per share payable on January 31, 2018 to shareholders of record on December 29, 2017. This  represents an increase of approx. 11% compared to the prior year and the previous quarter.

$LLY {{ '2017-12-04T13:20:47+0000' | timeago}} • Announcement

FDA approves $LLY's Taltz, an injectable drug used to treat psoiratic arthritis. Taltz was first approved by FDA in March 2016 for the treatment of moderate-to-severe plaque psoriasis.

$GMED {{ '2017-12-01T13:40:37+0000' | timeago}} • Announcement

$GMED, a musculoskeletal solutions company, reported positive results from its 7-year clinical trial on SECURE-C Cervical Artificial Disc in the treatment of cervical disc disease. SECURE-C, which is designed for disc reconstruction and motion preservation at the operated disc level, showed superior success rate compared to conventional therapies.

Recent Transcripts

SCHN (Schnitzer Steel Industries, Inc.)
Tuesday, January 9 2018 - 4:30pm
SHLO (Shiloh Industries Inc.)
Friday, January 5 2018 - 1:00pm
ENZ (Enzo Biochem Inc.)
Friday, December 8 2017 - 1:30pm
FVE (Five Star Quality Care Inc.)
Thursday, November 9 2017 - 3:00pm
GMED (Globus Medical, Inc.)
Wednesday, November 8 2017 - 10:30pm
IVC (Invacare Corporation)
Wednesday, November 8 2017 - 1:30pm
INGN (Inogen, Inc.)
Tuesday, November 7 2017 - 9:30pm
PKOH (Park-Ohio Holdings Corp.)
Tuesday, November 7 2017 - 3:00pm
HAE (Haemonetics Corporation)
Tuesday, November 7 2017 - 1:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
EBS (Emergent BioSolutions, Inc.)
Thursday, November 2 2017 - 9:00pm
FMS (Fresenius Medical Care AG & Co. KGAA)
Thursday, November 2 2017 - 8:30pm
RTIX (RTI Surgical Inc.)
Thursday, November 2 2017 - 12:30pm
WMGI (Wright Medical Group N.V.)
Wednesday, November 1 2017 - 8:30pm
EVHC (Envision Healthcare Holdings, Inc.)
Wednesday, November 1 2017 - 12:30pm
SYK (Stryker Corporation)
Thursday, October 26 2017 - 8:30pm
TRS (TriMas Corporation)
Thursday, October 26 2017 - 2:00pm
AIT (Applied Industrial Technologies, Inc.)
Wednesday, October 25 2017 - 2:00pm
GSK (GlaxoSmithKline plc)
Wednesday, October 25 2017 - 1:00pm
EW (Edwards Lifesciences Corp.)
Tuesday, October 24 2017 - 9:00pm

AlphaGraphics you may like